1. Home
  2. /
  3. Featured

Featured


August 2017

COAnalyzer Benchmarking Software for Practices

The Community Oncology Alliance (COA) and COA Pharmacy Association (COPA) has launched COAnalyzer.Net a new, completely free benchmarking tool for managing your oncology practices. It allows practices to maximize operations with real-time data.

Read Full
April 2018

2018 Community Oncology Practice Impact Report

1,653 Community Oncology Clinics and/or Practices Have Closed, Been Acquired by Hospitals, Merged, or Reported Financial Struggles Since 2008 Misguided Public Policies Continue Push and Pull on Community Oncology Practices The 2018 Community Oncology Alliance (COA) Practice Impact Report tracks the changing landscape of community cancer care in the United States. This is the seventh

Download (PDF) Read Full
December 2018

COA Comments on IPI for Medicare Part B Drugs

The Honorable Seema Verma, Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-5528-ANPRM P.O. Box 8016 Baltimore, MD 21244-8013 Re: Medicare Program; International Pricing Index Model for Medicare Part B Drugs; CMS-5528- ANPRM Dear Administrator Verma: On behalf of the Board of Directors of the Community Oncology Alliance (COA),

Download (PDF) Read Full
February 2019

Community Oncology Alliance: 2018 Year in Review

Introduction In 2018, the assault on patient access to local and affordable cancer care provided by community oncologists, upon which over half of all Americans rely, continued. The work of the Community Oncology Alliance (COA) repelled, repealed, or slowed down a record number of significant challenges to patients and practices, including proposed cuts to

Download (PDF) Read Full
March 2019

COA Comments: CMS CAR-T Cell Therapy Proposed Coverage Determination

COA Submits Formal Comments to CMS on Proposed CAR-T Cell Therapy Coverage Determination Today the Community Oncology Alliance (COA) submitted a formal comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding a proposed national coverage determination memo for CAR-T cell therapy. While COA is pleased that CMS is moving in the direction

Read Full